BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
3/11/2022 12:39:22 AM | Browse: 394 | Download: 901
 |
Received |
|
2021-09-01 16:46 |
|
Peer-Review Started |
|
2021-09-01 16:50 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-11-08 09:49 |
|
Revised |
|
2021-11-21 08:30 |
|
Second Decision |
|
2022-02-08 05:59 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2022-02-10 10:37 |
|
Articles in Press |
|
2022-02-10 10:37 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2022-02-19 13:18 |
|
Publish the Manuscript Online |
|
2022-03-11 00:39 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Case Report |
| Article Title |
Dual biologic therapy with ocrelizumab for multiple sclerosis and vedolizumab for Crohn’s disease: A case report and review of literature
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Michael Au, Nikola Mitrev, Rupert W Leong and Viraj Kariyawasam |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Michael Au, MBBS, Doctor, Doctor, Department of Gastroenterology and Hepatology, Blacktown and Mt Druitt Hospitals, Western Sydney Local Health District, Blacktown and Mt Druitt Hospitals, Blacktown and Mt Druitt Hospitals, Sydney 2148, New South Wales, Australia. michael.au@my.jcu.edu.au |
| Key Words |
Dual biologic therapy; Combination; Immunosuppression; Safety; Autoimmune; Case report |
| Core Tip |
This paper describes the use of two biologics for the treatment of Crohn's disease and multiple sclerosis. Only a few papers have reported the safety and efficacy of these treatments due to inherent concerns regarding immunosuppression, infection, and malignancy. We present the case of a patient who was safely treated with vedolizumab and ocrelizumab. The combination of biologics may be a safe and effective treatment for immune-mediated diseases. |
| Publish Date |
2022-03-11 00:39 |
| Citation |
Au M, Mitrev N, Leong RW, Kariyawasam V. Dual biologic therapy with ocrelizumab for multiple sclerosis and vedolizumab for Crohn’s disease: A case report and review of literature. World J Clin Cases 2022; 10(8): 2569-2576 |
| URL |
https://www.wjgnet.com/2307-8960/full/v10/i8/2569.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v10.i8.2569 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
